Kornimate/medical-research-clean huggingface dataset:
relationship between nutritional status, hand grip strength, and fatigue in hospitalized older adults with type 2 diabetes mellitus.

Conditions: Type 2 Diabetes Mellitus

Summary: as the proportion of the elderly population increases, so does the number of people suffering from diabetes mellitus (dm). fatigue is common in elderly patients with type 2 diabetes, and malnutrition may lead to a decrease in muscle strength, thereby aggravating their fatigue symptoms; however, there is still a lack of relevant research on this group in taiwan. therefore, the purposes of this study are to understand the current status and correlation of basic attributes, nutritional status, handgrip strength and fatigue in hospitalized older adults with type 2 diabetes mellitus.

diabetes mellitus (dm)is increasing among the elderly population in taiwan, and fatigue is a common troublesome symptom that likely impacts their quality of life and diabetes self-management. malnutrition is one of the causes of fatigue symptoms in the elderly, and the worse the nutritional status, the worse the hand grip strength performance; the better the grip strength performance, the lower the degree of fatigue symptoms. it can be inferred that the worse the nutritional status, the worse the handgrip strength, which will in turn have an aggravating impact on fatigue symptoms. according to previous literature, handgrip strength may be an important mediating variable between nutritional status and fatigue. however, there are still no relevant studies on hospitalized older adults with type 2 diabetes mellitus. therefore, the purposes of this study are to: (1) understand the basic attributes, nutritional status, handgrip strength and fatigue symptoms in hospitalized older adults with type 2 diabetes mellitus. (2) explore the correlation between nutritional status, handgrip strength and fatigue symptoms in hospitalized older adults with type 2 diabetes mellitus, so as to serve as a reference for future clinical care to improve fatigue in elderly patients with type 2 diabetes mellitus. this study adopted a cross-sectional, correlational design, using structured questionnaires and a camry digital handgrip dynamometer to collect data. participants will be recruited from a metabolism \& endocrinology ward at a medical center in northern taiwan using purposive sampling. the chinese version of a structured questionnaire, including the demographic and clinical characteristic form, the mini nutritional assessment , and the fatigue symptom inventory will be used. a sample of 54 participants with type 2 diabetes mellitus will be recruited.

Eligibility criteria:
inclusion criteria: * people who are aged 60 or above * diagnosed with type 2 diabetes mellitus * conscious and agree to participate in the study. exclusion criteria: * people who have a cognitive impairment or unable to communicate * unable to use the handgrip dynamometer with their dominant hand * under active treatment for cancer.
subcostal transverse abdominis plane block for epigastric cardiac pacemaker operation

Conditions: Congenital Heart Disease

Summary: this prospective randomized controlled trial aims to examine the effect of subcostal transverse abdominis plane block on the postoperative pain and opioid consumption in patients (12y≤ age) who will undergo epigastric cardiac pacemaker operation. patients will be allocated to either the sc tap(subcostal transverse abdominis plane block) group or the control group (no block). bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5ml/kg for each side, max 20ml for each side) under ultrasound-guidance at the end of surgery. the pain score at 10 min after pacu admin, 1, 6, 24 hours after the surgery, the total opioid consumption at 12, and 24 hours after the surgery, the total dose of additional rescue analgesia (intravenous ketololac or nalbuphine) at 12 and 24 hour after the surgery will be recorded.

this prospective randomized controlled trial aims to examine the effect of subcostal transverse abdominis plane block on the postoperative pain and opioid consumption in patients (12y≤ age) who will undergo epigastric cardiac pacemaker operation. patients will be allocated to either the sc tap(subcostal transverse abdominis plane block) group or the control group (no block). bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5ml/kg for each side, max 20ml for each side) under ultrasound-guidance at the end of surgery. the pain score at 10 min after pacu admin, 1, 6, 24 hours after the surgery, the total opioid consumption at 12, and 24 hours after the surgery, the total dose of additional rescue analgesia (intravenous ketololac, acetaminophen, or fentanil) at 12 and 24 hour after the surgery will be recorded.

Eligibility criteria:
inclusion criteria: - patients who will undergo epigastric cardiac pacemaker operation. (12≤ years) exclusion criteria: * allergy to opioid * allergy to local anesthetics * coagulation disorder * disease in the central and peripheral nervous system * significant renal impairment (creatinine\> 3.0 mg/dl) * significant hepatic impairment (aspartate transaminase\> 120 unit/l, alanine aminotransferase\> 120 unit/l)

Keywords: pacemaker
psychodynamic therapy for co-occurring borderline personality disorder and alcohol use disorder

Conditions: Borderline Personality Disorder; Alcohol Use Disorder

Summary: the purpose of the study is to determine the feasibility and effectiveness of a modified form of psychodynamic psychotherapy for persons suffering from co-occurring borderline personality disorder and an alcohol use disorder.

borderline personality disorder (bpd) is a condition that can cause significant distress and increased risk of death. many persons with bpd also have an alcohol use disorder (aud) and there is evidence that this can worsen the outcome and course of both disorders. a manual-based form of psychodynamic therapy (pt), labeled dynamic deconstructive psychotherapy, has been developed for particularly challenging patients with bpd, especially those with co-occurring substance use disorders. it aims to remediate specific neurocognitive capacities that are responsible for processing of emotional experiences, and so diminishes symptoms of bpd and promotes the development of a coherent and differentiated self-structure. pt has been shown to be helpful for bpd, but has not been tested for people who have bpd with co-occurring substance use disorders. the proposed study is a randomized controlled trial of pt for persons with bpd and co-occurring aud that will generate some initial data that can be used to determine the need and feasibility for further outcome studies. participants are randomized to either a study group receiving weekly pt or to a control group receiving usual care. enrollment is 15 participants in each group. the study group will receive 12-18 months of pt, with naturalistic follow-up. outcome measures are administered by a research assistant at enrollment, 3 months, 6 months, 9 months, 12 months, and 30 months. the investigators anticipate that the pt group will show trends towards better retention in treatment and greater reduction in parasuicides, alcohol misuse, and institutional care. if so, this would have important and positive implications for the large group of patients who suffer from bpd and co-occurring aud.

Eligibility criteria:
inclusion criteria: * age between 18 and 45 years * meets diagnostic criteria for borderline personality disorder and for active alcohol abuse or dependence * at least average intelligence exclusion criteria: * meets diagnostic criteria for schizophrenia, or schizoaffective disorder

Keywords: borderline alcohol substance psychodynamic psychotherapy psychoanalytic
single shot versus continuous adductor canal block in patients undergoing total knee arthroplasty

Conditions: Rheumatism Knee

Summary: adductor canal block (acb) has emerged as an option for postoperative regional analgesia in patients undergoing total knee arthroplasty (tka).

various approaches to the performance of peripheral nerve blocks for postoperative pain control in patients undergoing tka have been described in the literature. these approaches include lumbar plexus block, femoral nerve block (fnb), with or without a sciatic nerve block, and most recently the acb. fnb is a commonly used modality for postoperative analgesia after tka. it is considered by some as the gold standard or the cornerstone of postoperative analgesia after tka. however, fnb reduces quadriceps muscle strength essential for mobilization and active contribution in any physical rehabilitation program. quadriceps weakness places the patients at risk of falling. which may be detrimental to postoperative recovery. the acb has recently emerged as an appealing alternative to fnb as it is predominately a sensory nerve block of a more distal branch of the femoral nerve ( the saphenous nerve).

Eligibility criteria:
inclusion criteria: * patients scheduled for primary total knee arthroplasty with * american society of anesthesiologists (asa) physical status i -iii, * mentally competent and able to give consent for enrollment in the study. exclusion criteria: 1. patient younger than 18 years old or older than 70 years old 2. allergy to local anesthetics, systemic opioids (fentanyl, morphine, hydromorphone, and any of the drugs included in the multimodal perioperative pain protocol. 3. revision surgeries were excluded. 4. impaired kidney functions and patients with coagulopathy were also excluded. 5. chronic pain syndromes and patients with chronic opioid use defined as the use of regular daily doses of systemic narcotics for the past 6 months prior to the surgery. 6. bmi of 40 or more 7. pregnancy (positive urine pregnancy test result in preop area on the morning of surgery)
study of human papillomavirus (hpv) 16 vaccine in the prevention of hpv 16 infection in 16- to 23-year-old females (v501-005)

Conditions: HPV 16 Infection

Summary: subjects received hpv 16 l1 vlp vaccine or placebo (1:1 ratio). endpoints included efficacy, immunogenicity, and safety.


Eligibility criteria:
inclusion criteria: * healthy, unmarried females age 16 to 23 years with intact uteri * not pregnant at enrollment * agreed to use effective contraception through month 7 of the study * a lifetime history of 0 to 5 male partners with whom the subjects engaged in at least one episode of insertive intercourse exclusion criteria: * no prior history of human papillomavirus (hpv) vaccination * no receipt of any other vaccination within 1 month prior to enrollment or plans to receive any other vaccination within 1 month prior to or after any dose of study vaccine * no prior history of an abnormal papanicolaou (pap) test showing squamous intraepithelial lesion (sil) or biopsy showing cervical intraepithelial neoplasia (cin)
interleukin-7 to improve clinical outcomes in lymphopenic patients with covid-19 infection ( iliad-7-us-i )

Conditions: COVID-19; Lymphocytopenia

Summary: comparison of the effects of cyt107 vs placebo administered im at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic covid-19 patients

approximately forty-eight (48) participants will be randomized 1:1 to receive (a) intramuscular (im) administration of cyt107 at 10 μg/kg followed, after 72hrs of observation, by 10 μg/kg twice a week for 3 weeks (maximum 7administrations adjusted to patient's length of stay in the hospital) or (b)intramuscular (im) placebo (normal saline) at the same frequency. the aim of the study is to test the ability of cyt107 to produce an immune reconstitution of these patients and observe possible association with a clinical improvement. this cohort excludes oncology patients on treatment

Eligibility criteria:
inclusion criteria: 1. a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation 2. men and women aged ≥ 25 - 80 (included) years of age 3. hospitalized patients with two absolute lymphocyte count (alc) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following hospitalization: 4. hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4l per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated / ventilated for respiratory failure 5. confirmed infection with covid-19 by any acceptable test available / utilized at each site 6. willingness and ability to practice contraception regardless of the gender of the patient during 5 month after last drug exposure 7. private insurance or government / institution financial support (through cms or other) exclusion criteria: 1. pregnancy or breast feeding 2. alt and/or ast \> 5 x uln 3. known, active auto-immune disease; 4. ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing 5. patients with past history of solid organ transplant 6. active tuberculosis, uncontrolled active hbv or hcv infection, hiv with positive viral load 7. hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours 8. patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-il-6r treatments like tocilizumab or sarilumab or anti-il-1 treatment like anakinra which should preferably be minimized 9. patients with baseline rockwood clinical frailty scale ≥ 6 at hospital admission 10. patients showing an increase of the news2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration) 11. patients under guardianship
long-term use of spiolto respimat in japanese patients with chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: study to assess the long-term safety and effectiveness of spiolto in japanese patients with chronic obstructive pulmonary disease (copd) in real-world setting


Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) by physician and need relief of various symptoms associated with long acting beta2 agonist (laba) or long acting muscarinic antagonist (lama). * patients who are prescribed tio+olo fdc 5µg/5µg for the first time exclusion criteria: * patients who have been registered once in this study (i.e., re-entry of patients is not allowed). * patients who are participating in a registry or clinical trial. * patients who have a contraindication to tio+olo fdc 5µg/5µg defined in the package insert for tio+olo fdc 5µg/5µg.
molecular biomarkers associated with degenerative joint disease in the knee

Conditions: Cartilage Diseases

Summary: this investigation describes a novel complex of structural degradation proteins that is associated with pain in individuals with meniscal pathology undergoing arthroscopic partial meniscectomy. the presence of the complex in the synovial fluid of the knee is sensitive and specific for the painful state compared with similar aged controls. the absence of the complex in asymptomatic controls makes it a useful biomarker for the disease state.

background: molecular biomarkers associated with knee pain may be useful as diagnostic tools, prognostic indicators, and surrogate endpoints for therapeutic trials. this study describes a novel complex of structural degradation proteins which are present in the knees of patients with meniscal pathology. methods: this prospective cohort study included 30 patients with knee pain, mechanical symptoms, and mri positive for meniscus tear who elected for arthroscopic partial meniscectomy after failing conservative management. synovial fluid was aspirated at the time of surgery and assayed for a complex of structural degradation proteins by means of heterogeneous elisa. the results were compared to knee aspirates from 10 asymptomatic volunteers with no pain. the complex was identified by a proteomic analysis of including multiplexed-bead immunoassay, purification by anion exchange and size exclusion chromatography, and mass spectrometry of individual chromatographic fractions.

Eligibility criteria:
inclusion criteria: * the presence of mechanical symptoms including locking, catching, or giving way; * positive physical exam findings including joint line tenderness, mcmurray's exam, or steinman's exam; and * mri of the knee positive for meniscus tear in a location correlating with physical examination. exclusion criteria: * the presence of high grade gonarthrosis including kellgren-lawrence grade iv; * a history of prior knee surgery or trauma; ligamentous incompetence on examination or mri; and * diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.

Keywords: biomarker knee arthroscopy pain
the effect of doxycycline 100mg and doxycycline 20mg in treatment of mild and moderate acne

Conditions: Acne; Inflammation

Summary: the purpose of this study is to compare the safety and efficacy of twice daily subantimicrobial dose doxycycline 20mg with daily doxycycline 100mg in treatment of mild and moderate acne.


Eligibility criteria:
inclusion criteria: * acne exclusion criteria: * pregnancy
personalized feedback intervention for alcohol and opioid use among adults with chronic pain

Conditions: Alcohol Drinking; Pain; Opioid Use; Feedback, Psychological

Summary: over one-quarter of american adults engage in hazardous drinking (i.e., a pattern of alcohol consumption that increases risk for harmful consequences), which is the third leading cause of preventable death in the u.s. rates of hazardous drinking are significantly higher among individuals with (vs. without) chronic pain. moreover, 20% of individuals prescribed opioids endorse concurrent alcohol and opioid use, which may interfere with chronic pain treatment and lead to dangerous/potentially fatal health effects. no interventions to date have targeted either hazardous drinking or concurrent use of alcohol and opioids in the context of chronic pain. the current four-year r01 builds upon our past work by developing a brief, single-session, computer-based, personalized feedback intervention (pfi) designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations, increase motivation and intention to reduce hazardous drinking, and reduce positive attitudes and intention regarding concurrent use of alcohol and prescription opioid medications. specifically, we will develop an integrated pfi for hazardous drinkers with chronic pain who are prescribed opioids (pa-pfi). our approach will follow a staged model consistent with nih guidelines for developing and standardizing behavioral interventions. phase ia activities will involve collecting qualitative and quantitative feedback from three iterative focus groups (n = 21) to refine intervention content and evaluate treatment acceptability and feasibility. phase ib activities will include a proof-of-concept and highly rigorous randomized clinical trial designed to compare pa-pfi to control pfi (c-pfi) among a sample of 174 hazardous drinkers with chronic pain who are currently prescribed opioid medications. this study represents an important and pivotal step in the larger landscape of translating basic research to more efficacious strategies for reducing hazardous drinking among underserved populations with medical comorbidities. this intervention would be highly disseminable and relevant to millions of hazardous drinkers with chronic pain. given the collective public health impact of chronic pain, hazardous drinking, and concurrent alcohol-prescription opioid use, we believe the current study will yield findings that enhance scientific knowledge, enhance our understanding of mechanisms in reciprocal pain-alcohol-opioid relations, and inform the development of novel treatments for hazardous drinkers with chronic pain that are adaptable and easily implemented across a variety of healthcare settings.


Eligibility criteria:
inclusion criteria: * ≥ 21 years of age * current hazardous drinker * current chronic pain * current use of prescription opioid medications. exclusion criteria: * current alcohol or other substance use treatment * not being fluent in english * current psychiatric distress or thought disorder.

Keywords: alcohol opioids pain
the predictive ability of 4mgs in ipf

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study investigates whether usual walking speed, measured by the 4 metre gait speed test (4mgs), and change in usual walking speed over 6 months predicts death and hospital admissions in patients with idiopathic pulmonary fibrosis.

this observational study is investigating a simple test of usual walking speed, measured using the 4 metre gait speed (4mgs) test in patients with a lung disease called idiopathic pulmonary fibrosis (ipf). drug development for this disease is slow in part because there is a lack of reliable measurements that can assess the effectiveness of treatment. death and hospital admissions are currently considered meaningful endpoints in research trials due to the lack of fully validated surrogate endpoints in ipf. using surrogate endpoints could reduce the sample size, cost and duration of clinical trials in ipf perhaps permitting more rapid drug development. slow walking speed has been shown to be consistently associated with survival and a risk factor for disability, institutionalisation and hospitalisation in older adults and people with another lung disease called chronic obstructive pulmonary disease (copd). we are interested to see whether usual walking speed and change in usual walking speed over 6 months predicts death and hospital admissions in ipf patients. this will help inform us of the potential use of 4mgs as a surrogate endpoint. to do this, participants who consent to taking part in the study will be timed walking at their usual walking speed over a distance of 4 metres (13.12 feet) at one time point and then six months later. incidence of mortality and non-elective hospital admissions will be assessed at 12 months.

Eligibility criteria:
inclusion criteria: * ipf diagnosis according to nice guidelines exclusion criteria: * significant co-morbidities that would limit walking ability, exercise capacity or make exercise unsafe (e.g. unstable ischaemic heart disease, neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation) * any patient whom the chief investigator feels it is unsafe to exercise (e.g. unstable cardiovascular disease) * any condition that precludes providing informed consent e.g. cognitive impairment or poor english

Keywords: gait speed mortality morbidity